HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

ANG Lifesciences India Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 21 filings·Updated 14 Aug 2026
Showing 10 of 21 filings.
14 Aug 20261 filing
ResultFinancial Results

ANG Lifesciences India Q1 FY2026: Standalone revenue ₹1,395.79 lakhs; consolidated ₹1,529.77 lakhs; losses

Standalone results

  • Revenue from operations at ₹1,395.79 lakhs; Total revenue ₹1,415.05 lakhs.
  • PBT before tax at ₹-451.12 lakhs; PAT at ₹-341.76 lakhs.
  • EPS (basic/diluted) at ₹-2.59 for quarter ended 30 June 2026.

Consolidated results

  • Revenue from operations at ₹1,529.77 lakhs; Total revenue ₹1,540.54 lakhs.
  • PBT before tax at ₹-557.95 lakhs; PAT at ₹-422.65 lakhs.
  • Auditors expressed unmodified opinion on standalone and consolidated results.
Filed 18:30View Source
7 Aug 20261 filing
Board Meeting

ANG Lifesciences to hold Aug 14 board meeting to approve unaudited Standalone & Consolidated Q1 results.

Meeting Details

  • Date: Friday, 14 August 2026; Time: 05:00 P.M.; Venue: Darbara Complex, SCO-113, Amritsar.

Key Agenda Items

  • Consider and approve Standalone and Consolidated Un-Audited financial results for quarter ended 30 June 2026.

Other Notes

  • Trading window closed from 01 July 2026 to 48 hours after results made public on 14 August 2026.
Filed 12:39View Source
5 Jun 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication of Audited Financial Results for the quarter and year ended March 31, 2026.

Filed 12:17View Source
29 May 20261 filing
Company UpdateReg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report 31.03.2026.

Filed 13:56View Source
17 Apr 20261 filing
OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Filed 11:36View Source
15 Apr 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018

Filed 16:32View Source
10 Apr 20261 filing
Company UpdateClarification

The Exchange has sought clarification from ANG Lifesciences India Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....

Filed 08:16View Source
25 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Intimation of closure of Trading Window.

Filed 15:28View Source
6 Feb 20261 filing
Company UpdateReg.24(A)-Annual Secretarial Compliance

Revised Annual Secretarial Report for the year ended 31.03.2025.

Filed 18:07View Source
5 Feb 20261 filing
Board Meeting

ANG Lifesciences India Ltd - 540694 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended And Nine Months Ended On 31St December, 2025.

🗓️ Meeting Details

  • Board meeting scheduled for Saturday, 14 February 2026 at 5:00 PM at registered office in Amritsar.

📊 Financial Results

  • Approval of standalone and consolidated unaudited financial results for quarter and nine months ended 31 December 2025.
Filed 13:47View Source
Showing 10 of 21 filings